Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. METHODS: We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level, 0.04), objective response rate (alpha level, 0.001), and progression-free survival (alpha level, 0.009) among patients with intermediate or poor prognostic risk. RESULTS: A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546 patients); 425 and 422, respectively, had intermediate or poor risk. At a median follow-up of 25.2 months in intermediate- and poor-risk patients, the 18-month overall survival rate was 75% (95% confidence interval [CI], 70 to 78) with nivolumab plus ipilimumab and 60% (95% CI, 55 to 65) with sunitinib; the median overall survival was not reached with nivolumab plus ipilimumab versus 26.0 months with sunitinib (hazard ratio for death, 0.63; P<0.001). The objective response rate was 42% versus 27% (P<0.001), and the complete response rate was 9% versus 1%. The median progression-free survival was 11.6 months and 8.4 months, respectively (hazard ratio for disease progression or death, 0.82; P=0.03, not significant per the prespecified 0.009 threshold). Treatment-related adverse events occurred in 509 of 547 patients (93%) in the nivolumab-plus-ipilimumab group and 521 of 535 patients (97%) in the sunitinib group; grade 3 or 4 events occurred in 250 patients (46%) and 335 patients (63%), respectively. Treatment-related adverse events leading to discontinuation occurred in 22% and 12% of the patients in the respective groups. CONCLUSIONS: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“In that study, patients were randomized either to that regimen or to sunitinib (a VEGF inhibitor); significant prolongation of PFS and overall survival was observed, with 42% of patients achieving a response (many of these durable)11,12.”
From Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial (2022) · cites this paper as [11]
In the citing paper
“Anti-PD-1/PD-L1 agents pared with chemotherapy have also improved response rates and survival in many diseases including lung cancer, triple negative breast cancer, head and neck squamous cell carcinoma, and others.12–14”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 1×
“Bone§ 95 (22) 97 (23) 112 (20) 119 (22)”
Self-citationSunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775 · cited 1×
“Diarrhea 145 (27) 21 (4) 278 (52) 28 (5)”
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 4×
“Female 111 (26) 121 (29) 137 (25) 151 (28)”
InfluentialTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003 · cited 1×
“Bone§ 95 (22) 97 (23) 112 (20) 119 (22)”
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Decreased appetite 75 (14) 7 (1) 133 (25) 5 (<1)”
Cited by
Items 201–300 of 1,016
Quatrini, L., Mariotti, F. R., Munari, E., Tumino, N., Vacca, P., & Moretta, L. (2020) · Cancers · doi:10.3390/cancers12113285 · Cited by 158
Anti-TIGIT therapies for solid tumors: a systematic review
Rousseau, A., Parisi, C., & Barlesi, F. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101184 · Cited by 158
Ghatalia, P., Gordetsky, J., Kuo, F., Dulaimi, E., Cai, K. Q., Devarajan, K., Bae, S., Naik, G., Chan, T. A., Uzzo, R., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0621-1 · Cited by 159
Self-citationClonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors
Leruste, A., Tosello, J., Ramos, R. N., Tauziède-Espariat, A., Brohard, S., Han, Z.-Y., Beccaria, K., Andrianteranagna, M., Caudana, P., Nikolic, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.008 · Cited by 161
Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
Khan, M., Zhao, Z., Arooj, S., Fu, Y., & Liao, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587460 · Cited by 158
Modeling clear cell renal cell carcinoma and therapeutic implications
Wolf, M. M., Kimryn Rathmell, W., & Beckermann, K. E. (2020) · Oncogene · doi:10.1038/s41388-020-1234-3 · Cited by 154
Bedke, J., Albiges, L. K., Umberto Capitanio, A., Giles, R. H., Hora, M., Lam, T. B. L., Ljungberg, B., Marconi, L. S., Klatte, T., Volpe, A., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.04.042 · Cited by 158
Self-citationSiva, S., Bressel, M., Wood, S., Shaw, M. G., Loi, S., Sandhu, S. K., Tran, B., Azad, A., Lewin, J. H., Cuff, K. E., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.12.006 · Cited by 164
Bailey, C. M., Liu, Y., Liu, M., Du, X., Devenport, M., Zheng, P., Liu, Y., & Wang, Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci150846 · Cited by 151
Santoni, M., Rizzo, A., Kucharz, J., Mollica, V., Rosellini, M., Marchetti, A., Tassinari, E., Monteiro, F. S. M., Soares, A., Molina‐Cerrillo, J., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03349-4 · Cited by 153
Wan, X., Zhang, Y., Tan, C., Zeng, X., & Peng, L. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7086 · Cited by 161
Cutaneous adverse events caused by immune checkpoint inhibitors
Quach, H. T., Johnson, D. B., LeBoeuf, N. R., Zwerner, J. P., & Dewan, A. K. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.09.054 · Cited by 160
Roles of CCL2-CCR2 Axis in the Tumor Microenvironment
Kadomoto, S., Izumi, K., & Mizokami, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168530 · Cited by 145
“However, in recent years, immune checkpoint inhibitors have become more important [96,97].”
BackgroundMcGregor, B. A., McKay, R. R., Braun, D. A., Werner, L. L., Gray, K. P., Flaifel, A., Signoretti, S., Hirsch, M. S., Steinharter, J. A., Bakouny, Z., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01882 · Cited by 159
“Median age, years (range) 52 (36-75) 62 (22-82) 61 (22-82)”
Self-citationTykodi, S. S., Gordan, L., Alter, R. S., Arrowsmith, E. R., Harrison, M. R., Percent, I. J., Singal, R., Veldhuizen, P. J. V., George, D. J., Hutson, T. E., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003844 · Cited by 155
Macrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention
Zhou, X., Liu, X., & Huang, L. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202006220 · Cited by 147
Lasorsa, F. M., di Meo, N. A., Rutigliano, M., Milella, M., Ferro, M., Pandolfo, S. D., Crocetto, F., Tătaru, O. S., Autorino, R., Battaglia, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11041071 · Cited by 162
“In an international multicenter phase 3 trial (CheckMate 214), where patients were randomly assigned, a combination of nivolumab plus ipilimumab was found to have a higher ORR and longer progression-free survival (PFS) in intermediate and poor-risk patients than sunitinib [115,116].”
BackgroundCombination therapy with PD-1 or PD-L1 inhibitors for cancer
Hayashi, H., & Nakagawa, K. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01548-1 · Cited by 156
Chowdhury, N., & Drake, C. G. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.07.009 · Cited by 160
Pal, S. K., McGregor, B., Suárez, C., Tsao, C.-K., Kelly, W., Vaishampayan, U., Pagliaro, L., Maughan, B. L., Loriot, Y., Castellano, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00939 · Cited by 140
Self-citationVano, Y. A., Elaidi, R., Bennamoun, M., Chevreau, C., Borchiellini, D., Pannier, D., Maillet, D., Gross‐Goupil, M., Tournigand, C., Laguerre, B., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00128-0 · Cited by 166
Self-citationBody composition and sarcopenia: The next-generation of personalized oncology and pharmacology?
Hilmi, M., Jouinot, A., Burns, R. G., Pigneur, F., Mounier, R., Gondin, J., Neuzillet, C., & Goldwasser, F. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.003 · Cited by 163
Clinical Review on the Management of Metastatic Renal Cell Carcinoma
Tran, J., & Ornstein, M. C. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00419 · Cited by 156
Pai, C.-C. S., Huang, J. T., Lu, X., Simons, D. M., Park, C., Chang, A., Tamaki, W., Liu, E., Roybal, K. T., Seagal, J., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.006 · Cited by 141
Liu, L., Bai, H., Wang, C., Seery, S., Wang, Z., Duan, J., Li, S., Xue, P., Wang, G., Sun, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.016 · Cited by 149
Apolo, A. B., Nadal, R., Girardi, D. M., Niglio, S. A., Ley, L., Cordes, L. M., Steinberg, S. M., Ortiz, O. S., Cadena, J., Diaz, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01652 · Cited by 143
“Median age, years (range) 56 (20-82) Male 48 (89)”
Treatment Landscape of Renal Cell Carcinoma
Chen, Y., Wang, L., Panian, J. A., Dhanji, S., Derweesh, I., Rose, B. S., Bagrodia, A., & McKay, R. R. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01161-5 · Cited by 140
Wallis, C. J. D., Novara, G., Marandino, L., Bex, A., Kamat, A. M., Karnes, R. J., Morgan, T. M., Mottet, N., Gillessen, S., Bossi, A., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.063 · Cited by 138
“Among the 436 N + I patients in CheckMate 214 who had immune-mediated TRAEs, 35% received high-dose glucocorticoids [100].”
Self-citationQuhal, F., Mori, K., Bruchbacher, A., Resch, I., Mostafaei, H., Pradère, B., Schuettfort, V. M., Laukhtina, E., Egawa, S., Fajković, H., et al. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.03.001 · Cited by 147
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Kuo, H., Khan, K. A., & Kerbel, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00886-y · Cited by 151
“149) in RCC (Supplementary Table 2)) have had disappointing preliminary results.”
InfluentialTyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
Rassy, E., Flippot, R., & Albiges, L. K. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920907504 · Cited by 143
The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer
Jørgensen, N., Persson, G., & Hviid, T. V. F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00911 · Cited by 151
Kooshkaki, O., Derakhshani, A., Hosseinkhani, N., Torabi, M., Safaei, S., Brunetti, O., Racanelli, V., Silvestris, N., & Baradaran, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124427 · Cited by 147
“Adverse events are generally manageable with established guidelines, including the use of corticosteroids for grade 3 or 4 events [70].”
BackgroundRIG-I activation is critical for responsiveness to checkpoint blockade
Heidegger, S. M., Wintges, A., Stritzke, F., Bek, S., Steiger, K., Koenig, P.-A., Göttert, S., Engleitner, T., Öllinger, R., Nedelko, T., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau8943 · Cited by 142
PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
Munari, E., Mariotti, F. R., Quatrini, L., Bertoglio, P., Tumino, N., Vacca, P., Eccher, A., Ciompi, F., Brunelli, M., Martignoni, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105123 · Cited by 153
The therapeutic implications of immunosuppressive tumor aerobic glycolysis
Reinfeld, B. I., Rathmell, W. K., Kim, T. K., & Rathmell, J. C. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00727-3 · Cited by 150
McDermott, D. F., Lee, J., Bjarnason, G. A., Larkin, J., Gafanov, R. A., Kochenderfer, M. D., Jensen, N. V., Donskov, F. N., Malik, J., Poprach, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02363 · Cited by 146
“Although the single-arm nature of this study limits conclusions, the safety data of the current analysis suggest that pembrolizumab monotherapy may be better tolerated than the approved PD-1–based and PD-L1–based combination therapies.(2-4) Treatment with pembrolizumab monotherapy may therefore be a potential treatmen…”
BackgroundMethodResultSelf-citationBedke, J., Albiges, L. K., Umberto Capitanio, A., Giles, R. H., Hora, M., Lam, T. B. L., Ljungberg, B., Marconi, L. S., Klatte, T., Volpe, A., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.12.005 · Cited by 133
Self-citationLiu, F., Qin, L., Liao, Z., Song, J., Yuan, C., Liu, Y., Wang, Y., Xu, H., Zhang, Q., Pei, Y., et al. (2020) · Experimental Hematology & Oncology · doi:10.1186/s40164-020-00165-3 · Cited by 126
Increasing cure rates of solid tumors by immune checkpoint inhibitors
Ma, W., Xue, R., Zhu, Z. G., Farrukh, H., Song, W., Li, T., Zheng, L., & Pan, C.-X. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00372-8 · Cited by 143
Immunosurveillance in clinical cancer management
Kroemer, G., Chan, T. A., Eggermont, A. M. M., & Galluzzi, L. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21818 · Cited by 123
Singla, N., Hutchinson, R. C., Ghandour, R. A., Freifeld, Y. N., Fang, D., Sagalowsky, A. I., Lotan, Y., Bagrodia, A., Margulis, V., Hammers, H. J., et al. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.02.029 · Cited by 127
Self-citationMechanisms of resistance to immune checkpoint inhibitors
Nagasaki, J., Ishino, T., & Togashi, Y. (2022) · Cancer Science · doi:10.1111/cas.15497 · Cited by 138
“8,9 The process in which T- cell activation leads to killing cancer cells is summarized in seven steps (Figure 1)34: (1) cancer antigen release from cancer cells, (2) presentation of cancer antigens via MHC molecules by antigen- presenting cells (APCs), (3) T- cell activation via recognition of cancer antigen in the c…”
BackgroundPD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
Hirsch, L., Zitvogel, L., Eggermont, A. M. M., & Marabelle, A. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0294-4 · Cited by 141
MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential
Penticuff, J. C., Woolbright, B. L., Sielecki, T. M., Weir, S. J., & Taylor, J. A. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0171-9 · Cited by 132
Shah, A. Y., Kotecha, R. R., Lemke, E., Chandramohan, A., Chaim, J. L., Msaouel, P., Xiao, L., Gao, J., Campbell, M. T., Zurita, A. J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.003 · Cited by 131
Self-citationBergerot, P., Lamb, P., Wang, E., & Pal, S. K. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1399 · Cited by 124
“PD-L1 expression on tumor cells and immune cells is a common feature of RCC (8, 15, 22) andUC (7, 30), although its role as a predictive biomarker is unclear.”
BackgroundInfluentialAggen, D. H., Ager, C. R., Obradović, A., Chowdhury, N., Ghasemzadeh, A., Mao, W., Chaimowitz, M. G., Bujanda, Z. A. L., Spina, C. S., Hawley, J. E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1610 · Cited by 132
“The current standard-of-care treatment for first-line metastatic RCC involves either combination PD-1/CTLA-4 blockade (4) or combining an anti-PD-1/PD-L1 therapy with a VEGF-targeted tyrosine kinase inhibitor (TKI), such as axitinib (5, 6).”
BackgroundWu, B. Y., Zhang, Q., & Sun, J. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0440-9 · Cited by 128
Telomerase-Targeted Cancer Immunotherapy
Mizukoshi, E., & Kaneko, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081823 · Cited by 120
Zhang, Y., Du, X., Liu, M., Tang, F., Zhang, P., Ai, C., Fields, J. K., Sundberg, E. J., Latinovic, O., Devenport, M., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0184-1 · Cited by 127
Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma
Auvray, M., Auclin, É., Barthélémy, P., Bono, P., Kellokumpu‐Lehtinen, P., Gross‐Goupil, M., de Velasco, G., Powles, T. B., Mouillet, G., Vano, Y. A., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.031 · Cited by 130
Self-citationImmune checkpoint inhibitors win the 2018 Nobel Prize
Huang, P., & Chang, J. W. (2019) · Biomedical Journal · doi:10.1016/j.bj.2019.09.002 · Cited by 150
“[24] Motzer RJ, Tannir NM, McDermott DF, Ar en Frontera O, Melichar B, Choueiri TK, et al.”
BackgroundYang, F., Markovic, S. N., Molina, J. R., Halfdanarson, T. R., Pagliaro, L. C., Chintakuntlawar, A. V., Li, R., Wei, J., Wang, L., Liu, B., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.12534 · Cited by 133
Targeting inflammation as cancer therapy
Wang, M., Chen, S., He, X., Yuan, Y., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01528-7 · Cited by 136
“The safety profile of pegilodecakin significantly differs from other interleukin therapies with frequent occurrence of the cytokine release syndrome [432].”
BackgroundVerheijden, R. J., de Groot, J. S., Fabriek, B. O., Hew, M. N., May, A. M., & Suijkerbuijk, K. P. M. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00191 · Cited by 134
The Prognostic and Therapeutic Value of PD-L1 in Glioma
Chen, R. Q., Liu, F., Qiu, X. Y., & Chen, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01503 · Cited by 131
“Currently, many other cancers such as renal carcinoma, colorectal cancer, lymphoma, head and neck carcinoma, bladder cancer, hepatocellular carcinoma and metastatic colorectal cancer are also approved for PD-1/PD-L1-targeting therapy (Ansell et al., 2015; Le et al., 2015; Ferris et al., 2016; Bellmunt et al., 2017; Mo…”
BackgroundImmune checkpoint inhibitor combinations: Current efforts and important aspects for success
Kon, E., & Benhar, I. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.07.004 · Cited by 129
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors
Adib, E., Nassar, A. H., Akl, E. W., Alaiwi, S. A., Nuzzo, P. V., Mouhieddine, T. H., Sonpavde, G., Haddad, R. I., Mouw, K. W., Giannakis, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0575 · Cited by 132
Self-citationShah, N. J., Al‐Shbool, G., Blackburn, M. J., Cook, M. R., Belouali, A., Liu, S. V., Madhavan, S., He, A. R., Atkins, M. B., Gibney, G. T., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0771-1 · Cited by 121
Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy
Carlson, R. D., Flickinger, J. C., & Snook, A. E. (2020) · Toxins · doi:10.3390/toxins12040241 · Cited by 146
Yu, Q., Xia, Y., Lin, Z., Qu, Y., Qi, Y., Chen, Y., Zhou, Q., Zeng, H., Wang, J., Chang, Y., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02563-2 · Cited by 133
“Besides TKIs, the result of CheckMate 214 research has shown the promising efficacy of immune checkpoint inhibitors (ICIs) for patients with advanced renal cell carcinoma [8], which means the focus of cancer therapy has transformed from the tumor itself to the tumor microenvironment (TME), to overcome the dysfunction…”
BackgroundIsik, B., Alexander, M. P., Manohar, S., Vaughan, L., Kottschade, L., Markovic, S., Lieske, J., Kukla, A., Leung, N., & Herrmann, S. M. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.01.013 · Cited by 112
Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
Kennedy, L. C., Bhatia, S., Thompson, J. A., & Grivas, P. D. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7310 · Cited by 122
Predictive biomarkers for response to immune checkpoint inhibition
Shum, B., Larkin, J., & Turajlic, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.036 · Cited by 134
The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment
Hu, H., Chen, Y., Tan, S., Wu, S., Huang, Y., Fu, S., Luo, F., & He, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.802846 · Cited by 117
“Nivolumab plus Ipilimumab in a phase 3 trial (NCT02231749) has provided significant benefits in untreated intermediate and poor-risk RCC patients with a higher 18month OS rate of 75% and objective responses rate (ORR) of 42%, compared to sunitinib with 18-month OS rate of 60% and ORR of 27% (78).”
BackgroundNew rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
Rassy, E., Parent, P., Lefort, F., Boussios, S., Baciarello, G., & Pavlidis, N. A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102882 · Cited by 124
Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
Shah, D., Soper, B. W., & Shopland, L. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190379 · Cited by 122
Geels, S. N., Moshensky, A., Sousa, R. S., Murat, C., Bustos, M. A., Walker, B. L., Singh, R., Harbour, S. N., Gutierrez, G., Hwang, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.013 · Cited by 140
Engineering Prodrug Nanomedicine for Cancer Immunotherapy
Yang, B., Gao, J., Pei, Q., Xu, H., & Yu, H. (2020) · Advanced Science · doi:10.1002/advs.202002365 · Cited by 118
Motzer, R. J., Choueiri, T. K., McDermott, D. F., Powles, T. B., Vano, Y. A., Gupta, S. K., Yao, J., Han, G. C., Ammar, R., Papillon‐Cavanagh, S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004316 · Cited by 123
Self-citationDuerinck, J., Schwarze, J. K., Awada, G., Tijtgat, J., Vaeyens, F., Bertels, C., Geens, W., Klein, S., Seynaeve, L., Cras, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002296 · Cited by 113
Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma
McKay, R. R., Bossé, D., & Choueiri, T. K. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0253 · Cited by 112
Self-citationClinical Insights Into Novel Immune Checkpoint Inhibitors
Lee, J. B., Ha, S.-J., & Kim, H. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.681320 · Cited by 112
Grassadonia, A., Sperduti, I., Vici, P., Iezzi, L., Brocco, D., Gamucci, T., Pizzuti, L., Maugeri‐Saccà, M., Marchetti, P., Cognetti, G., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120542 · Cited by 126
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Cadranel, J. L., Canellas, A., Matton, L., Darrason, M., Parrot, A., Naccache, J., Lavolé, A., Ruppert, A.-M., & Fallet, V. (2019) · European Respiratory Review · doi:10.1183/16000617.0058-2019 · Cited by 117
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Ciciola, P., Cascetta, P., Bianco, C., Formisano, L., & Bianco, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030675 · Cited by 122
“In contrast, Motzer and colleagues have observed no correlation between PD-L1 expression and survival benefit in patients receiving nivolumab plus ipilimumab in the CheckMate 214 trial, where a longer PFS rate was observed in patients receiving immunotherapy with PD-L1 expression of 1% or more [120].”
Bhatt, R. S., Berjis, A., Konge, J. C., Mahoney, K. M., Klee, A. N., Freeman, S. S., Chen, C.-H., Jegede, O. A., Catalano, P. J., Pignon, J., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0315 · Cited by 125
Self-citationShen, L., Zhang, Y., Li, Z., Zhang, X., Gao, X., Liu, B., Wang, Y., Ba, Y., Li, N., Zhang, R., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03450-4 · Cited by 135
“The ORR was also higher in the cadonilimab group (65.2% versus 48.9%), and the DoR doubled in the cadonilimab group compared with the chemotherapy group, consistent with other trials using nivolumab plus ipilimumab 24–26 .”
InfluentialAgonistic CD40 Antibodies in Cancer Treatment
Djureinovic, D., Wang, M., & Kluger, H. M. (2021) · Cancers · doi:10.3390/cancers13061302 · Cited by 120
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Pansy, K., Uhl, B., Krstić, J., Szmyra, M., Fechter, K., Santiso, A., Thüminger, L., Greinix, H., Kargl, J., Prochazka, K. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413311 · Cited by 124
Next-generation combination approaches for immune checkpoint therapy
Goswami, S., Pauken, K. E., Wang, L., & Sharma, P. (2024) · Nature Immunology · doi:10.1038/s41590-024-02015-4 · Cited by 127
Self-citationEbrahimi, H., Dizman, N., Meza, L., Malhotra, J., Li, X., Dorff, T., Frankel, P., Llamas-Quitiquit, M., Hsu, J., Zengin, Z. B., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03086-4 · Cited by 109
“%) will achieve a complete response (CR) to these therapies, the vast majority will ultimately experience disease progression on treatment 4–7 .”
Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
Carril-Ajuria, L., Santos, M., Roldán‐Romero, J. M., Rodríguez‐Antona, C., & de Velasco, G. (2019) · Cancers · doi:10.3390/cancers12010016 · Cited by 130
“, non-small cell lung cancer), in RCC it is not useful [59,61,62].”
BackgroundMHC-I genotype and tumor mutational burden predict response to immunotherapy
Goodman, A. M., Castro, A., Pyke, R. M., Okamura, R., Kato, S., Riviere, P., Frampton, G., Sokol, E., Zhang, X., Ball, E. D., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00743-4 · Cited by 109
McGregor, B. A., Campbell, M. T., Xie, W., Farah, S., Bilen, M. A., Schmidt, A. L., Sonpavde, G., Kilbridge, K. L., Choudhury, A. D., Mortazavi, A., et al. (2020) · Cancer · doi:10.1002/cncr.33328 · Cited by 123
“Cohort 2: adrenal tumors (n = 18) 1 8 9 6 (1-20)”
Self-citationDobosz, P., Stępień, M., Golke, A., & Dzieciątkowski, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052847 · Cited by 131
Bakouny, Z., Zarif, T. E., Dudani, S., Wells, J. C., Gan, C. L., Donskov, F. N., Shapiro, J., Davis, I. D., Parnis, F., Ravi, P. K., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.10.004 · Cited by 123
Self-citationMazumder, S., Higgins, P. J., & Samarakoon, R. (2023) · Cancers · doi:10.3390/cancers15041316 · Cited by 131
Ligero, M., Garcia-Ruiz, A., Viaplana, C., Villacampa, G., Raciti, M. V., Landa, J., Matos, I., Martin-Liberal, J., Ochoa-de-Olza, M., Hierro, C., et al. (2021) · Radiology · doi:10.1148/radiol.2021200928 · Cited by 107
A Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events
Naidoo, J., Zhang, J., Lipson, E. J., Forde, P. M., Suresh, K., Moseley, K. F., Mehta, S., Kwatra, S. G., Parian, A. M., Kim, A. K., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7268 · Cited by 107
Zhou, A., Bai, Y., Song, Y., Luo, H., Ren, X.-B., Wang, X., Shi, B., Fu, C., Cheng, Y., Liu, J., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0839 · Cited by 106
Role of the adaptive immune response in sepsis
Brady, J., Horie, S., & Laffey, J. G. (2020) · Intensive Care Medicine Experimental · doi:10.1186/s40635-020-00309-z · Cited by 129
“mAbs targeting the PD1-PD-L1 pathway have already been licenced for therapeutic use in cancer and have shown their effectiveness in reducing tumour burden [92].”
BackgroundThe Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma
Monjarás-Ávila, C. U., Lorenzo‐Leal, A. C., Luque-Badillo, A. C., D’Costa, N. M., Chavez-Munoz, C. I., & Bach, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097946 · Cited by 128
“Similarly, the combination of nivolumab and ipilimumab has improved progression-free survival and overall survival compared to sunitinib, a standard first-line therapy for advanced ccRCC [62].”
BackgroundPD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma
Zelba, H., Bedke, J., Hennenlotter, J., Mostböck, S., Zettl, M., Zichner, T., Chandran, A., Stenzl, A., Rammensee, H.-G., & Gouttefangeas, C. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0146 · Cited by 104
Brown, L. C., Tucker, M. D., Sedhom, R., Schwartz, E. B., Zhu, J., Kao, C., Labriola, M., Gupta, R. T., Marin, D., Wu, Y. S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001792 · Cited by 122
Lisi, L., Lacal, P. M., Martire, M., Navarra, P., & Graziani, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105997 · Cited by 115
Heinrich, S., Craig, A. J., Ma, L., Heinrich, B., Greten, T. F., & Wang, X. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.036 · Cited by 115
Weiss, S. A., Djureinovic, D., Jessel, S., Krykbaeva, I., Zhang, L., Jilaveanu, L., Ralabate, A., Johnson, B., Levit, N. S., Anderson, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0903 · Cited by 102
Recent developments with immunotherapy for hepatocellular carcinoma
Waidmann, O. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1499722 · Cited by 107
“Combined treatment with nivolumab and Ipilimumab has also been shown to be superior to standard first-line treatment with sunitinib in renal cell cancer [28].”
Background
Metadata
- Authors
- Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C. K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M.-O., Bracarda, S., Barrios, C. H., Tomita, Y., Castellano, D., Rini, B. I., Chen, A. C., Mekan, S., McHenry, M. B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H. J., & Escudier, B.
- Affiliations
- Brigham and Women's Hospital (US)
- From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) — both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana–Farber/Harvard Cancer Center (D.F.M.), and Dana–Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman),...
- ORCID
- Motzer, Robert J.
- Tannir, Nizar M.
- McDermott, David F.
- Melichar, Bohuslav
- Choueiri, Toni K.
- Plimack, Elizabeth R.
- Barthélémy, Philippe
- Porta, Camillo
- George, Saby
- Powles, Thomas
- Donskov, Frede
- Kollmannsberger, Christian K.
- Salman, Pamela
- Gurney, Howard
- Ravaud, Alain
- Grimm, Marc-Oliver
- Barrios, Carlos H.
- Tomita, Yoshihiko
- Castellano, Daniel
- Rini, Brian I.
- Mekan, Sabeen
- McHenry, M. Brent
- Sharma, Padmanee
- Hammers, Hans J.
- Escudier, Bernard
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-05
- Volume
- 378
- Issue
- 14
- Pages
- 1277-1290
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5972549
- OpenAlex
- W2792937256
- Cited by
- 4,656
- References
- 31
- Citations by year
- 2026: 305 · 2025: 416 · 2024: 510 · 2023: 601 · 2022: 656 · 2021: 708 · 2020: 684 · 2019: 562 · 2018: 209
- FWCI
- 408.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Ono Pharmaceutical Company Limited
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab plus ipilimumab, sunitinib, advanced renal cell carcinoma, clear cell renal cell carcinoma, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, combination immunotherapy, overall survival, objective response rate, progression-free survival, treatment-related adverse events, immune-related adverse events, first-line therapy
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Sunitinib, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Humans, Indoles, Kidney Neoplasms, Male, Middle Aged, Pyrroles, Quality of Life, Risk, Survival Rate, Survival Analysis, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.